The absence of enhanced disease with wild type respiratory syncytial virus infection occurring after receipt of live, attenuated, respiratory syncytial virus vaccines

Vaccine

Volumn 25, Issue 42, 2007, Pages 7372-7378

  Wright, Peter F ^a   Karron, Ruth A ^b   Belshe, Robert B ^c   Shi, Jian R ^a   Randolph, Valerie B ^d   Collins, Peter L ^e   O'Shea, Alice F ^a   Gruber, William C ^d   Murphy, Brian R ^e  

^a VANDERBILT UNIVERSITY   (United States)

^b JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

^c SAINT LOUIS UNIVERSITY   (United States)

^d WYETH RESEARCH   (United States)

^e NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

Author keywords

Respiratory syncytial virus; Safety; Vaccines

Indexed keywords

FORMALDEHYDE; PLACEBO; RESPIRATORY SYNCYTIAL VIRUS VACCINE;

ARTICLE; CHILD HEALTH; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; FOLLOW UP; HUMAN; INFANT; LOWER RESPIRATORY TRACT INFECTION; MAJOR CLINICAL STUDY; PRESCHOOL CHILD; PRIORITY JOURNAL; RESPIRATORY SYNCYTIAL PNEUMOVIRUS; SEROLOGY; UPPER RESPIRATORY TRACT INFECTION; VIRUS INFECTION; WILD TYPE;

ANTIBODIES, VIRAL; CASE-CONTROL STUDIES; HUMANS; INFANT; RESPIRATORY SYNCYTIAL VIRUS INFECTIONS; RESPIRATORY SYNCYTIAL VIRUS VACCINES; RESPIRATORY SYNCYTIAL VIRUS, HUMAN; SAFETY; VACCINES, ATTENUATED;

EID: 34748850172     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2007.08.014     Document Type: Article

References (21)

1. Karron R.A., Wright P.F., Belshe R.B., Thumar B., Casey R., Newman F., et al. Identification of a recombinant live attenuated respiratory syncytial virus vaccine candidate that is highly attenuated in infants. J Infect Dis 191 7 (2005) 1093-1104
2. Karron R.A., Wright P.F., Crowe Jr. J.E., Clements-Mann M.L., Thompson J., Makhene M., et al. Evaluation of two live, cold-passaged, temperature-sensitive respiratory syncytial virus vaccines in chimpanzees and in human adults, infants, and children. J Infect Dis 176 6 (1997) 1428-1436
3. Wright P.F., Karron R.A., Belshe R.B., Thompson J., Crowe Jr. J.E., Boyce T.G., et al. Evaluation of a live, cold-passaged, temperature-sensitive, respiratory syncytial virus vaccine candidate in infancy. J Infect Dis 182 5 (2000) 1331-1342
4. Wright P.F., Karron R.A., Madhi S.A., Treanor J.J., King J.C., O'Shea A., et al. The interferon antagonist NS2 protein of respiratory syncytial virus is an important virulence determinant for humans. J Infect Dis 193 4 (2006) 573-581
5. Chin J., Magoffin R.L., Shearer L.A., Schieble J.H., and Lennette E.H. Field evaluation of a respiratory syncytial virus vaccine and a trivalent parainfluenza virus vaccine in a pediatric population. Am J Epidemiol 89 4 (1969) 449-463
6. Fulginiti V.A., Eller J.J., Sieber O.F., Joyner J.W., Minamitani M., and Meiklejohn G. Respiratory virus immunization. I. A field trial of two inactivated respiratory virus vaccines; an aqueous trivalent parainfluenza virus vaccine and an alum-precipitated respiratory syncytial virus vaccine. Am J Epidemiol 89 4 (1969) 435-448
7. Kapikian A.Z., Mitchell R.H., Chanock R.M., Shvedoff R.A., and Stewart C.E. An epidemiologic study of altered clinical reactivity to respiratory syncytial (RS) virus infection in children previously vaccinated with an inactivated RS virus vaccine. Am J Epidemiol 89 4 (1969) 405-421
8. Kim H.W., Canchola J.G., Brandt C.D., Pyles G., Chanock R.M., Jensen K., et al. Respiratory syncytial virus disease in infants despite prior administration of antigenic inactivated vaccine. Am J Epidemiol 89 4 (1969) 422-434
9. Peebles Jr. R.S., and Graham B.S. Pathogenesis of respiratory syncytial virus infection in the murine model. Proc Am Thorac Soc 2 2 (2005) 110-115
10. Polack F.P., Teng M.N., Collins P.L., Prince G.A., Exner M., Regele H., et al. A role for immune complexes in enhanced respiratory syncytial virus disease. J Exp Med 196 6 (2002) 859-865
11. Connors M., Crowe Jr. J.E., Firestone C.Y., Murphy B.R., and Collins P.L. A cold-passaged, attenuated strain of human respiratory syncytial virus contains mutations in the F and L genes. Virology 208 2 (1995) 478-484
12. Crowe Jr. J.E., Firestone C.Y., Whitehead S.S., Collins P.L., and Murphy B.R. Acquisition of the ts phenotype by a chemically mutagenized cold-passaged human respiratory syncytial virus vaccine candidate results from the acquisition of a single mutation in the polymerase (L) gene. Virus Genes 13 3 (1996) 269-273
13. Firestone C.Y., Whitehead S.S., Collins P.L., Murphy B.R., and Crowe Jr. J.E. Nucleotide sequence analysis of the respiratory syncytial virus subgroup A cold-passaged (cp) temperature sensitive (ts) cpts-248/404 live attenuated virus vaccine candidate. Virology 225 2 (1996) 419-422
14. Prince G.A., Curtis S.J., Yim K.C., and Porter D.D. Vaccine-enhanced respiratory syncytial virus disease in cotton rats following immunization with Lot 100 or a newly prepared reference vaccine. J Gen Virol 82 Pt 12 (2001) 2881-2888
15. Whitehead S.S., Firestone C.Y., Karron R.A., Crowe Jr. J.E., Elkins W.R., Collins P.L., et al. Addition of a missense mutation present in the L gene of respiratory syncytial virus (RSV) cpts530/1030 to RSV vaccine candidate cpts248/404 increases its attenuation and temperature sensitivity. J Virol 73 2 (1999) 871-877
16. Whitehead S.S., Bukreyev A., Teng M.N., Firestone C.Y., St Claire M., Elkins W.R., et al. Recombinant respiratory syncytial virus bearing a deletion of either the NS2 or SH gene is attenuated in chimpanzees. J Virol 73 4 (1999) 3438-3442
17. Collins P.L., Whitehead S.S., Bukreyev A., Fearns R., Teng M.N., Juhasz K., et al. Rational design of live-attenuated recombinant vaccine virus for human respiratory syncytial virus by reverse genetics. Adv Virus Res 54 (1999) 423-451
18. Wright P.F., Gruber W.C., Peters M., Reed G., Zhu Y., Robinson F., et al. Illness severity, viral shedding, and antibody responses in infants hospitalized with bronchiolitis caused by respiratory syncytial virus. J Infect Dis 185 8 (2002) 1011-1018
19. Fisher R.G., Gruber W.C., Edwards K.M., Reed G.W., Tollefson S.J., Thompson J.M., et al. Twenty years of outpatient respiratory syncytial virus infection: a framework for vaccine efficacy trials. Pediatrics 99 2 (1997) E7
20. Belshe R.B., Mendelman P.M., Treanor J., King J., Gruber W.C., Piedra P., et al. The efficacy of live attenuated, cold-adapted, trivalent, intranasal influenzavirus vaccine in children. N Engl J Med 338 20 (1998) 1405-1412
21. The IMpact-RSV Study GroupPalivizumab. a humanized respiratory syncytial virus monoclonal antibody, reduces hospitalization from respiratory syncytial virus infection in high-risk infants. Pediatrics 102 3 Pt 1 (1998) 531-537